Geoff MacKay, Avrobio CEO
Avrobio halts PhII study for Fabry disease in another setback, shuttering lead program
An oft-troubled Fabry disease program got the axe Tuesday as its parent company will shut down development after reviewing some new Phase II data. And …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.